Project Name: Collaborative Working- Novartis Re-imagining Care Pathways Collaborative Working Project (NCRP CWP) for Mount Vernon Hospital, East & North Hertfordshire NHS Trust Breast Cancer Service
Project Summary:
The Reimagining Care Pathways CWP is a service offered by Novartis, which comprises a series of workshops, with the aim of providing pathway mapping support to the CW Partner (healthcare and service teams) to:
- Improve efficiency and service effectiveness for the benefit of patient care.
- Address the local challenges they face in the delivery of patient care.
The programme facilitates area teams (Trust or ICS) to identify areas for efficiency within their service for prioritisation. The programme will be carried out in a number of different institutions. The service is facilitated by the Novartis Solutions Implementation Manager (SIM) Team.
Planned Milestones:
| Milestone Description | Milestone Delivery Date | Milestone Evidence | |
|---|---|---|---|
| 1 | SIM & CW Partner’s key stakeholders: Both parties agree the scope of the NRCP CWP and arrange the dates for the stakeholder’s interviews. | Execution of collaborative working agreement (CWA) date +4 weeks | SIM: Meeting minutes |
| 2 | SIM & CW Partner: Mapping the Pathway – 1:1 interviews (as a guide, allow 1 hour for each interview and aim to have them all completed within circa 4 weeks) | Execution of collaborative working agreement (CWA) date +8 weeks | SIM: Meeting minutes |
| 3 | SIM & CW Partner: Feedback/Consultation with NHS post workshop (as a guide, no later than +4 weeks from workshop) | Execution of collaborative working agreement (CWA) date +14 weeks | SIM: Final Pathway Map Report detailing any identified any unmet needs / efficiency constraints in their service. SIM: Meeting minutes |
| 4 | SIM & CW Partner: Post workshop Feedback / Consultation | Execution of collaborative working agreement (CWA) date +14 weeks | SIM: Customer prioritisation of areas of change |
Expected Benefits:
Anticipated benefits for patients:
We anticipate that some of the benefits for patients could include;
- Potentially fewer visits and shorter waiting times as a result of a more efficient clinical pathway
- Faster and more equitable access to the complete range of NICE approved treatment options.
- Quality care improvements aligned to established best practices
Anticipated benefits for the organisation(s):
Improved understanding of the current service pathway, and associated efficiencies and inefficiencies. Potential to lead to solutions which could allow the CW Partner’s organisation to enhance both patient experience and outcomes.
Anticipated benefits to Novartis:
Understanding of possible opportunities to partner with the CW Partner to enhance patient outcomes and experience. Better understanding of patients,’ carers and customers’ needs, which may inform future service offerings, and synergies between needs of the customer and value of Novartis offerings.
Start Date & Duration: March 2024, 14 weeks
UK2403281384
Project Name: Collaborative Working- Novartis Re-imagining Care Pathways Collaborative Working Project (NCRP CWP) for Mount Vernon Hospital, East & North Hertfordshire NHS Trust Breast Cancer Service
Partner Organisation(s): Mount Vernon Hospital, East & North Hertfordshire NHS Trust, Rickmansworth Road Northwood Middlesex HA6 2RN (the “CW Partner”)
Completion Date: September 2024
Outcomes Summary:
Despite meeting its targets and delivering timely care, the Breast Cancer service at Mount Vernon Hospital faces challenges from the expected rise in oral treatments. The key priorities of this project were to map the flow of activity within the service and identify opportunities and pinch points to improve patient care, minimise disparity of care between different pathways (injection versus oral when appropriate and based on clinical monitoring requirements and clinical decisions as well as to improve the booking-in and patient notification process.
Key Project Outcomes Data:
A report and patient pathway map was developed in collaboration with the CWP partner which demonstrated the following:
- Improved understanding of the current service pathway, leading to potential solutions for enhancing patient experience and outcomes.
- Better understanding of patients’ needs, which may inform future service offerings.
- Potentially fewer visits and shorter waiting times due to a more efficient clinical pathway.
- Faster and more equitable access to the complete range of NICE approved treatment options.
Outcomes:
4 Key areas of need were identified: administration, oral SACT(Systematic Anti-Cancer Therapy) pathway, pharmacy and digital technology implementation. Short, medium and long term wins were suggested within these 4 themes and the project team identified and prioritsed those that would be achievable in our final meeting. It was agreed that changing the pharmacy pathway, including moving certain roles and responsibilities from the outsourced team to the internal pharmacy team and implementing a digital PIFU(Patient Initiated follow-up) pathway were challenges that could be worked on without further support from Novartis. Administration and oral SACT pathway challenges were identified as needs that Novartis could potentially support with in the near future.
Conclusion:
This project provided a real-time snapshot of the Oral SACT patient pathway at Mount Vernon. By mapping this pathway, we identified bottlenecks and proposed solutions to alleviate them. The insights and observations from the report have informed a potential collaborative working project, where Novartis may be able to support these solutions.
FA-11342533